PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11081765-5 2000 Advanced age, higher initial serum creatinine, history of hypertension, diabetes and atrial fibrillation predict the onset of GFR impairment associated with blockade of the renin-angiotensin system. Creatinine 35-45 renin Homo sapiens 173-178 11412630-4 2001 RESULTS: The renal resistive index was significantly higher in the cirrhotic patients with ascites (0.68) than in the compensated cirrhotics (0.63) and was significantly correlated with the serum levels of creatinine,urinary excretion of sodium, plasmatic renin activity and plasmatic concentration of aldosterone. Creatinine 206-216 renin Homo sapiens 256-261 14551679-10 2003 Patients with PAC/renin activity less than 2 had higher total volume of infused fluid, serum creatinine level, and fractional excretion of sodium values; aldosterone and serum creatinine were negatively correlated. Creatinine 93-103 renin Homo sapiens 18-23 14551679-10 2003 Patients with PAC/renin activity less than 2 had higher total volume of infused fluid, serum creatinine level, and fractional excretion of sodium values; aldosterone and serum creatinine were negatively correlated. Creatinine 176-186 renin Homo sapiens 18-23 11403100-6 2001 A significant negative correlation was obtained between serum creatinine and plasma renin activity (r=-0.842, p<0.001) in macroalbuminuric NIDDM patients. Creatinine 62-72 renin Homo sapiens 84-89 11403100-13 2001 Thus plasma renin activity is decreased in diabetic nephropathy and negatively correlates with serum creatinine. Creatinine 101-111 renin Homo sapiens 12-17 2821091-5 1987 By stepwise logistic analysis, only hyponatremia (or an elevated plasma renin activity) and enalapril therapy independently predicted the decline in creatinine clearance during converting enzyme inhibition. Creatinine 149-159 renin Homo sapiens 72-77 9702931-3 1998 In subjects with LVH (SV1 + R(V5, V6) > or = 3.5mV), a stepwise multiple regression analysis revealed that SV1 + R(V5, V6) was associated with plasma renin activity (PRA) in both males and females, and with creatinine concentration (Cr) in males. Creatinine 210-220 renin Homo sapiens 153-158 9462378-8 1998 Increased renin levels were observed in ten of the 43 patients and were associated with impaired creatinine clearance. Creatinine 97-107 renin Homo sapiens 10-15 2183472-4 1990 The authors found significantly higher levels of serum creatinine in low-renin EH. Creatinine 55-65 renin Homo sapiens 73-78 2143594-2 1990 The existence of tissue renin angiotensin system (RAS) has been widely suggested in the recent literature by 2 main approaches: first, a dissociation between antihypertensive effects of angiotensin converting enzyme (ACE) inhibitors and the levels of stimulation of the circulating RAS; secondly, by the demonstration of the presence of the 3 key-proteins of the system (angiotensinogen, creatinine, and converting enzyme) within the 3 main target-organs of hypertension (i.e. kidney, heart and vessels). Creatinine 388-398 renin Homo sapiens 24-29 3037893-9 1987 Significant correlations between serum creatinine levels and plasma renin activity have been observed. Creatinine 39-49 renin Homo sapiens 68-73 3019586-3 1986 Among the 29 patients with a pretreatment renal perfusion pressure under 70 mm Hg, patients with preserved renal function (creatinine clearance greater than 50 ml/min/1.73 m2) had markedly elevated values for plasma renin activity (11.8 +/- 3.8 ng/ml/hr) and showed a significant decline in creatinine clearance after converting-enzyme inhibition (61.1 +/- 3.0 to 45.9 +/- 5.3 ml/min/1.73 m2; p less than .05). Creatinine 123-133 renin Homo sapiens 216-221 3019586-3 1986 Among the 29 patients with a pretreatment renal perfusion pressure under 70 mm Hg, patients with preserved renal function (creatinine clearance greater than 50 ml/min/1.73 m2) had markedly elevated values for plasma renin activity (11.8 +/- 3.8 ng/ml/hr) and showed a significant decline in creatinine clearance after converting-enzyme inhibition (61.1 +/- 3.0 to 45.9 +/- 5.3 ml/min/1.73 m2; p less than .05). Creatinine 291-301 renin Homo sapiens 216-221 3019586-4 1986 In contrast, although similar with respect to all pretreatment demographic, hemodynamic, and clinical variables, patients with a creatinine clearance under 50 ml/min/1.73 m2 had low values for plasma renin activity (3.4 +/- 0.8 ng/ml/hr) and, despite similar drug-induced decreases in systemic blood pressure, showed no change in creatinine clearance after therapy with captopril or enalapril (32.6 +/- 2.5 to 41.4 +/- 3.8 ml/min/1.73 m2). Creatinine 129-139 renin Homo sapiens 200-205 3019586-5 1986 Changes in creatinine clearance varied linearly and inversely with pretreatment values for plasma renin activity (r = - .64, p less than .001); converting-enzyme inhibition effectively abolished the pretreatment difference in renal function seen in the high- and low-renin subgroups. Creatinine 11-21 renin Homo sapiens 98-103 3019586-5 1986 Changes in creatinine clearance varied linearly and inversely with pretreatment values for plasma renin activity (r = - .64, p less than .001); converting-enzyme inhibition effectively abolished the pretreatment difference in renal function seen in the high- and low-renin subgroups. Creatinine 11-21 renin Homo sapiens 267-272 6754152-4 1982 Creatinine clearance, albumin concentration and hematocrit were lower in low renin patients than in patients with medium renin activity. Creatinine 0-10 renin Homo sapiens 77-82 3510938-8 1986 Finally, creatinine clearance corrected excretion of PGI-M, as an estimation of relative plasma levels correlates both with plasma renin activity and plasma aldosterone in the 31 subjects who presented with ascites. Creatinine 9-19 renin Homo sapiens 131-136 2998675-3 1985 In six patients with plasma creatinine levels greater than or equal to 3 mg/dl, aldosterone excretion decreased after 4 weeks of captopril, from 7.5 +/- 3.1 to 1.8 +/- 0.5 micrograms/24 hr, whereas plasma renin activity increased from 0.6 +/- 0.2 to 4.4 +/- 1.1 ng/ml/hr (P less than 0.05). Creatinine 28-38 renin Homo sapiens 205-210 6387263-8 1984 Statistical evaluation of subjects with renovascular and essential hypertension still revealed significant differences in creatinine when the patients with initial plasma renin activity (PRA) below and above 6 ng/ml X 3 h were compared separately. Creatinine 122-132 renin Homo sapiens 171-176 6822131-5 1983 The changes in renin activity correlated significantly (p less than 0.01) with the small changes in endogenous creatinine clearance (r = 0.84). Creatinine 111-121 renin Homo sapiens 15-20 3514728-6 1986 Levels of plasma renin activity ranged between 1 and 46 ng/ml per h (average 14.7 +/- 5.7) and correlated with serum sodium (r = 0.77, p less than 0.025), serum creatinine (r = 0.73, p less than 0.025) and right atrial pressure (r = 0.67, p less than 0.05). Creatinine 161-171 renin Homo sapiens 17-22 3528886-5 1986 Changes in creatinine were markedly higher in cases with bilateral renal artery stenosis and/or in those with a very high initial plasma renin activity (greater than 15 ng/ml X 3 h). Creatinine 11-21 renin Homo sapiens 137-142 6369515-5 1983 Renin and angiotensin II levels were both related to creatinine clearance, which was often reduced, but it is not clear as to which was cause and which effect. Creatinine 53-63 renin Homo sapiens 0-5 7032555-7 1981 Decreases in creatinine clearance correlated with lower blood pressure during captopril and were most obvious in patients with high baseline plasma renin activity. Creatinine 13-23 renin Homo sapiens 148-153 663820-7 1978 Patients with the greatest increase in creatinine clearance showed the largest rise in substrate concentration and fall in renin and aldosterone secretion, suggesting a dynamic relationship between these factors. Creatinine 39-49 renin Homo sapiens 123-128 455818-3 1979 In 2 who developed acute renal failure without porto-systemic encephalopathy, plasma renin activity was noted to rise before serum creatinine and to return to initial levels after 3 or 4 days while renal failure persisted. Creatinine 131-141 renin Homo sapiens 85-90 31248950-12 2019 CONCLUSIONS: Adding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria. Creatinine 160-170 renin Homo sapiens 84-89 935120-1 1976 Hypertensive patients with various renal lesions and a mean plasma creatinine of 2mg/100ml showed increases (p is less than 0.05) in mean exchangeable sodium and plasma renin activity, while blood volume was not altered significantly. Creatinine 67-77 renin Homo sapiens 169-174 6023776-5 1967 Concomitant measurements of endogenous creatinine clearance and the rates of excretion of sodium and potassium suggest that a fall in renal arterial perfusion resulting from upright posture induces increased release of renin and the subsequent secondary stimulation of aldosterone secretion. Creatinine 39-49 renin Homo sapiens 219-224 33624028-6 2021 The risk of AKI, CD, and their combination was increased in patients with higher neutrophil count/creatinine (heart rate (HR) = 3.7, 95% cardiac index (CI) 1.9-7.1; HR = 2.7, 95% CI 1.6-4.6; HR = 3.2, 95% CI 2.1-4.9); NL-ratio/creatinine (HR = 2.1, 95% CI 1.6-4.1; HR = 2.2, 95% CI 1.3-3.8; HR = 2.3, 95% CI 1.5-3.5); and hsCRP (HR = 1.8, 95% CI 0.9-3.5; HR = 2.2, 95% CI 1.3-3.6; HR = 1.9, 95% CI 1.2-2.8) after adjustment for age, diabetes, hypertension, previous heart failure, kidney function, haemodynamic instability at admission, statin, and renin-angiotensin-aldosterone antagonists use. Creatinine 98-108 renin Homo sapiens 549-554 31688312-9 2020 The random effect model analysis revealed a mean reduction of 2.63 ng/ml/h (95% CI: -4.46 to -0.8; P = 0.005) in plasma renin activity (PRA), mean reduction of 255.37 pg/ml (95% CI: -441.23 to -69.5; P = 0.007) in plasma aldosterone levels, and a mean increase of 0.14 mg/dl (95% CI: -0.13 to 0.41; P = 0.32) in serum creatinine levels favouring add-on alpha agonist group. Creatinine 318-328 renin Homo sapiens 120-125 25070937-10 2014 The pro-renin level correlated positively with serum creatinine at presentation (correlation coefficient 0.671, P-value<0.001), blood urea at initial presentation (correlation coefficient 0.684, P-value<0.001), serum creatinine at follow-up (correlation coefficient 0.546, P-value<0.001) and blood urea at follow-up (correlation 0.603, P-value<0.001). Creatinine 53-63 renin Homo sapiens 8-13 29345404-1 2018 AIMS: To assess variability in systolic blood pressure (SBP) and albuminuria (urinary albumin creatinine ratio [UACR]) responses in patients with type 2 diabetes mellitus initiating renin angiotensin aldosterone system (RAAS) inhibition, and to assess the association of response variability with cardiovascular outcomes. Creatinine 94-104 renin Homo sapiens 182-187 31079532-4 2019 Active renin was increased in urine samples from patients with DKD (n=36), compared with those without DKD (n=38; 3.2 versus 1.3 pg/mg creatinine; P<0.001). Creatinine 135-145 renin Homo sapiens 7-12 28279964-0 2017 Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. Creatinine 6-16 renin Homo sapiens 33-38 25070937-10 2014 The pro-renin level correlated positively with serum creatinine at presentation (correlation coefficient 0.671, P-value<0.001), blood urea at initial presentation (correlation coefficient 0.684, P-value<0.001), serum creatinine at follow-up (correlation coefficient 0.546, P-value<0.001) and blood urea at follow-up (correlation 0.603, P-value<0.001). Creatinine 223-233 renin Homo sapiens 8-13 24702136-9 2014 A logistic regression model revealed that the odds of having aortic stiffness were increased by 56% with a 1-SD increase of log albumin:creatinine ratio after adjustment for age, gender, duration of diabetes, HbA1c , blood pressure, HDL and LDL cholesterol, estimated glomerular filtration rate, BMI, usage of renin-angiotensin system antagonists, statins and insulin. Creatinine 136-146 renin Homo sapiens 310-315 25349694-8 2014 A rise of serum creatinine was noted during fasting in 60.4% of patients by Day 7 and was associated with intake of renin angiotensin aldosterone system antagonists [relative risk (RR) 2, P = 0.002]. Creatinine 16-26 renin Homo sapiens 116-121 26105881-8 2013 Urinary protein/creatinine was not related to iRAS activity (males and non-pregnant females) but in pregnancy was related to prorenin and active renin/creatinine (r=0.45, P=0.02, n=26 r=0.47, P<0.001, n=50). Creatinine 16-26 renin Homo sapiens 128-133 26105881-9 2013 Urinary albumin/creatinine was related to uAGT and active renin/creatinine in pregnancy (r=0.39, P=0.005, n=51; r=0.37, P=0.008, n=51). Creatinine 16-26 renin Homo sapiens 58-63 22345094-9 2012 CONCLUSIONS: This post-hoc analysis of the AVOID study suggests that renin inhibition with aliskiren 300 mg once daily added to losartan 100 mg once daily plus optimal antihypertensive therapy provides reductions in urinary albumin creatinine ratio that are efficacious in all, but particularly in poorly controlled, diabetic patients. Creatinine 232-242 renin Homo sapiens 69-74 18775113-6 2008 Changes in the serum creatinine concentration and hyperkalemia are complications of antihypertensive therapy in patients with chronic kidney disease that can be successfully managed to allow continued use of renin-angiotensin blockade. Creatinine 21-31 renin Homo sapiens 208-213 17699488-6 2007 In patients with primary aldosteronism, plasma active renin levels that were higher than the lower limit of detection (2.5 pg/ml) were associated with higher BP, plasma potassium, and albuminuria and lower creatinine clearance. Creatinine 206-216 renin Homo sapiens 54-59 17699488-8 2007 Creatinine clearance was correlated directly with plasma aldosterone and inversely with renin. Creatinine 0-10 renin Homo sapiens 88-93 16914958-8 2006 The elimination of rigid limitations to increases in serum potassium and serum creatinine is suggested as a means to enhance prescription of renin-angiotensin system inhibitors. Creatinine 79-89 renin Homo sapiens 141-146 22644350-5 2012 Changes in serum creatinine, although an important marker of renal function, may not be associated with adverse outcomes, especially if they are transient and a consequence of more aggressive decongestion, or the appropriate titration of drugs affecting the renin-angiotensin-aldosterone axis. Creatinine 17-27 renin Homo sapiens 258-263